Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
作者信息
Taylor D R, Kinney C D, McDevitt D G
出版信息
Br J Clin Pharmacol. 1982 Apr;13(4):569-71. doi: 10.1111/j.1365-2125.1982.tb01423.x.
Abstract
摘要
相似文献
1
Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
Br J Clin Pharmacol. 1982 Apr;13(4):569-71. doi: 10.1111/j.1365-2125.1982.tb01423.x.
2
Clinical use of controlled-release theophylline in chronic airways obstruction.
J Int Med Res. 1987 Nov-Dec;15(6):391-6. doi: 10.1177/030006058701500610.
3
The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
Br J Clin Pract. 1985 Apr;39(4):148-53.
4
5
Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.
Br J Clin Pharmacol. 1984 Jul;18(1):27-30. doi: 10.1111/j.1365-2125.1984.tb05017.x.
6
Dose response relation to oral theophylline in severe chronic obstructive airways disease.
BMJ. 1988 Dec 10;297(6662):1506-10. doi: 10.1136/bmj.297.6662.1506.
7
[Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies].
Presse Med. 1988 Feb 13;17(5):193-6.
8
Comparison of standard- and sustained-release theophylline tablets in patients with chronic obstructive pulmonary disease.
Am J Hosp Pharm. 1979 May;36(5):613-7.
9
Treatment of chronic obstructive pulmonary disease with two sustained-release theophylline preparations.
J Int Med Res. 1987 Nov-Dec;15(6):352-60. doi: 10.1177/030006058701500604.
10
Use of serum theophylline level as a guide to optimum therapy in patients with chronic obstructive lung disease.
J Clin Pharmacol. 1990 Apr;30(4):324-9. doi: 10.1002/j.1552-4604.1990.tb03601.x.
引用本文的文献
1
Prediction of optimum oral theophylline dose in patients with obstructive airways disease.
Br J Clin Pharmacol. 1983 Jun;15(6):689-94. doi: 10.1111/j.1365-2125.1983.tb01551.x.
2
Is circadian variation in theophylline trough serum concentrations determined by time of dosing?
Br J Clin Pharmacol. 1984 Jun;17(6):777-9. doi: 10.1111/j.1365-2125.1984.tb02419.x.
本文引用的文献
1
Plasma theophylline concentrations following the oral administration of microcrystalline theophylline and a new sustained-release theophylline preparation to normal subjects.
Eur J Clin Pharmacol. 1980 Oct;18(4):351-4. doi: 10.1007/BF00561394.
2
Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.
Clin Pharmacol Ther. 1972 May-Jun;13(3):349-60. doi: 10.1002/cpt1972133349.
3
Rational intravenous doses of theophylline.
N Engl J Med. 1973 Sep 20;289(12):600-3. doi: 10.1056/NEJM197309202891202.
4
Dosage of theophylline in bronchial asthma.
N Engl J Med. 1975 Jun 5;292(23):1218-22. doi: 10.1056/NEJM197506052922305.
5
Measurement of theophylline in plasma by high performance liquid chromatography.
Br J Clin Pharmacol. 1976 Oct;3(5):947-8. doi: 10.1111/j.1365-2125.1976.tb00657.x.
6
Clinical pharmacokinetics of theophylline.
Clin Pharmacokinet. 1978 Jul-Aug;3(4):267-93. doi: 10.2165/00003088-197803040-00002.
Zotero 插件